Description du projet
Traitement et gestion plus efficaces du cancer du foie
Le cancer du foie, qui affecte environ un million de personnes par an dans le monde, est un problème de santé publique, l’Europe enregistrant environ 90 000 nouveaux cas chaque année. Il s’agit de la troisième cause de mortalité liée au cancer dans le monde. Le carcinome hépatocellulaire (CHC) et l’hépatoblastome (HB), en particulier, sont confrontés à de complexes obstacles thérapeutiques liés au manque de compréhension de leurs caractéristiques. Pour faire face à cette crise, le projet THRIVE, financé par l’UE, adopte une approche pluridisciplinaire qui rassemble 13 partenaires dans huit pays. S’appuyant sur des technologies de pointe telles que le séquençage de l’ARN unicellulaire et l’IA, THRIVE entend faire la lumière sur les populations à risque, la biologie des tumeurs et la résistance aux traitements. En analysant 6 700 échantillons provenant de 15 cohortes de patients, THRIVE se propose de développer des biomarqueurs pour les thérapies actuelles et de nouveaux traitements abordables.
Objectif
"Liver cancer is a major health problem with ~1 million cases diagnosed each year (~90,000 cases/year in Europe), and it is the 3rd cause of cancer-related mortality worldwide. Hepatocellular carcinoma (HCC) in adults, and hepatoblastoma (HB) in children are considered poorly understood cancers. HCC is a difficult-to-cure cancer (curation rate ~ 30%) with poor outcome (median survival < 2 years in advanced stages), due to limited understanding of at-risk populations, resistance to therapies and lack of precision oncology. In HB, outcomes are hampered in one fourth of cases due disease progression after surgical intervention and adjuvant chemotherapy.
THRIVE aims by to improve the outcome of both paediatric and adult liver cancer patients by understanding at-risk populations, tumour-host interactions, and by developing biomarkers for current therapies and novel, affordable treatments to overcome resistance. THRIVE brings together a strong, multidisciplinary team -13 partners, from 8 countries- with complementary expertise to leverage cutting-edge technologies (single-cell RNASeq, spatial transcriptomics, microbiota analysis, artificial intelligence, mouse models and patient-derived organoids) and sectors (i.e academia, SMEs, hospitals, patient associations) and 15 patient cohorts (~6,700 samples).
THRIVE expects to: 1) Define molecular features of cancer predisposition and at-risk populations for development of liver cancer. 2) Develop a complete human liver cancer blueprint of tumour, immune, stromal cells and intra-tumoral microbiomes. 3) Identify AI-based and molecular markers of response to treatments. 4) Implement a preclinical drug testing platform for discovery of affordable therapies with high social impact. 5) Maximize the impact in the European society by integrating SSH disciplines, delivering accessible and re-usable data and tools to support EU initiatives such as the UNCAN.eu platform, and by influencing policymakers and health professionals.
This action is part of the Cancer Mission cluster of projects on “Understanding (tumour-host interactions)""."
Champ scientifique
Mots‑clés
Programme(s)
- HORIZON.2.1 - Health Main Programme
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
08036 Barcelona
Espagne